Intra-Cellular Therapies (ITCI) has resolved patent litigation with Sandoz (SDZNY) regarding Caplyta through a settlement agreement.

RBC Capital views this positively and believes that the terms of the settlement are more favorable than expected, which could benefit Intra-Cellular's revenue from Caplyta.

The settlement is significant as Sandoz is the first of seven ANDA filers to reach a deal. RBC Capital maintains an Outperform rating on Intra-Cellular shares and sets a price target of $108. The firm suggests that investors should consider buying the stock following this settlement, indicating confidence in Intra-Cellular's ability to navigate the competitive landscape for its product.